OTC Monograph Drug User Fee Program (OMUFA); Understanding FY 2025 User Fees and Registration
Similar Posts
FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
The U.S. Food and Drug Administration today established a “green list” import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.GDUFA III Reauthorization
Generic drug user fees make it possible for FDA and industry to continue to ensure that the American public has access to safe, effective and high-quality generic drugs. The implementation of the Generic Drug User Fee Amendments (GDUFA) encompasses a wide range of activities that fall within the scoHetero Labs Limited Warehouse 483 – 9/26/25
Record Date: 09/26/2025
Entity Name: Hetero Labs Limited (Warehouse)
FEI Number: 3040501127
Record Type: 483
Country: India
Establishment Type: WarehouseBioresearch Monitoring Information System (BMIS)
Bioresearch Monitoring Information System (BMIS) background page with download file.Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceuticals, Los Angeles, CA. 483, Second Amended 483 Issued 03/23/2017
Task Description Request Please post to the 2017 Pharmacy Inspections and Related Records Web page
Record Date 03/23/2017
FEI Number 3013341563
Firm Name Fusion IV Pharmaceuticals Inc. dba Axia Pharmaceutical
Record Type 483
State CA
Establishment Type Producer of Sterile Drug Products